Description
While TREM2 was identified as a key target for allosteric modulation, the specific signaling cascades that become dysregulated in disease variants remain unclear. This mechanistic gap prevents rational design of precision modulators that could restore normal pruning function.
Source: Debate session sess_sda-2026-04-01-gap-v2-691b42f1 (Analysis: sda-2026-04-01-gap-v2-691b42f1)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:20.255361+00:00”, “resolution_summary”: “Resolved by hypothesis h-5d68a7d2: Microglial TREM2 Activation to Enhance Synaptic Pruning Regulation. Supporting evidence includes debate sess_SDA-2026-04-11-gap-debate-20260410-111113-052488a8.”, “match_counts”: {“hypothesis_matches”: 5, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-5d68a7d2”, “title”: “Microglial TREM2 Activation to Enhance Synaptic Pruning Regulation”, “score”: 0.32, “reason”: “3 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-16-frontier-connectomics-84acb35a”, “target_gene”: “Microglial TREM2”, “target_pathway”: null, “disease”: “connectomics”, “composite_score”: 0.53463, “confidence_score”: 0.65, “status”: “proposed”, “pubmed_evidence_ids”: [“19219025”, “26551527”, “26928458”, “29186337”, “31171641”]}, {“id”: “h-aa1f5de5cd”, “title”: “TREM2 haploinsufficiency dysregulates microglial synaptic surveillance, switching from protective ‘disease-associated microglia’ to neurotoxic ‘inflammasome-active’ states”, “score”: 0.243, “reason”: “18 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-02-gap-synaptic-pruning-microglia”, “target_gene”: “TREM2, TYROBP (DAP12), APOE”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.7, “confidence_score”: 0.22, “status”: “proposed”, “pubmed_evidence_ids”: [“26598730”, “27753624”, “28602351”, “28802038”, “29070674”]}, {“id”: “h-var-ce41f0efd7”, “title”: “Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling”, “score”: 0.24, “reason”: “22 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-03-26abc5e5f9f2”, “target_gene”: “TREM2”, “target_pathway”: “microglial phagocytosis and lysosomal degradation”, “disease”: “neuroscience”, “composite_score”: 0.827143, “confidence_score”: 0.75, “status”: “promoted”, “pubmed_evidence_ids”: [“20301376”, “31285742”, “40392508”, “40639927”, “40898879”]}, {“id”: “h-48858e2a”, “title”: “Microglial TREM2-SYK Pathway Enhancement”, “score”: 0.233, “reason”: “17 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-03-gap-seaad-v4-20260402065846”, “target_gene”: “TREM2”, “target_pathway”: “TREM2/TYROBP microglial signaling”, “disease”: “neurodegeneration”, “composite_score”: 0.798, “confidence_score”: 0.7, “status”: “promoted”, “pubmed_evidence_ids”: [“35921534”, “36306735”, “37099634”, “38712251”, “39048816”]}, {“id”: “h-var-799795f6af”, “title”: “TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming”, “score”: 0.232, “reason”: “17 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402”, “target_gene”: “TREM2, CSF1R”, “target_pathway”: “TREM2/CSF1R metabolic cross-talk → microglial metabolic dysfunction”, “disease”: “neurodegeneration”, “composite_score”: 0.748363, “confidence_score”: 0.78, “status”: “proposed”, “pubmed_evidence_ids”: [“20301376”, “24047521”, “28802038”, “30258234”, “31932797”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-11-gap-debate-20260410-111113-052488a8”, “title”: “The debate revealed fundamental uncertainty about whether enhancing TYROBP-SYK signaling would be beneficial or harmful, with existing drugs being SYK inhibitors. This mechanistic gap is critical for determining if downstream TREM2 pathway activation is a viable therapeutic strategy.\n\nSource: Debate session sess_sda-2026-04-01-001 (Analysis: sda-2026-04-01-001)”, “score”: 0.358, “reason”: “7 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-11-gap-debate-20260410-111113-052488a8”, “quality_score”: 0.3, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-11-gap-debate-20260410-100405-abac24bc”, “title”: “The debate proposed biphasic TREM2 modulation but couldn’t define when to switch from inhibition to activation. The Skeptic noted AD lacks discrete temporal phases, making this critical for any temporal therapeutic strategy.\n\nSource: Debate session sess_SDA-2026-04-10-trem2-ad (Analysis: trem2-ad)”, “score”: 0.337, “reason”: “6 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-11-gap-debate-20260410-100405-abac24bc”, “quality_score”: 0.3, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-debate-20260410-112522-57d1cc4f”, “title”: “While TREM2 was identified as critical for microglial senescence, the debate lacked fine-grained temporal data on when and how TREM2 signaling shifts from neuroprotective to pathogenic. Understanding this transition timing is essential for intervention strategies.\n\nSource: Debate session sess_SDA-2026-04-02-gap-aging-mouse-brain-v5-20260402 (Analysis: SDA-2026-04-02-gap-aging-mouse-brain-v5-20260402)”, “score”: 0.332, “reason”: “6 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-15-gap-debate-20260410-112522-57d1cc4f”, “quality_score”: 0.73, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-11-gap-debate-20260410-100409-e0118210”, “title”: “The debate proposed temporal TREM2 modulation but couldn’t define when to switch from inhibition to activation phases. This fundamental timing question remains unresolved despite being critical for therapeutic success.\n\nSource: Debate session sess_SDA-2026-04-10-trem2-ad (Analysis: trem2-ad)”, “score”: 0.332, “reason”: “6 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-11-gap-debate-20260410-100409-e0118210”, “quality_score”: 0.3, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-11-gap-debate-20260410-112636-141592ba”, “title”: “The debate highlighted that TREM2 therapeutic targeting remains contested across disease stages, but no clear framework exists for when to activate versus inhibit TREM2 signaling. This timing question is critical for clinical translation but remains empirically unresolved.\n\nSource: Debate session sess_SDA-2026-04-02-gap-001 (Analysis: SDA-2026-04-02-gap-001)”, “score”: 0.32, “reason”: “6 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-11-gap-debate-20260410-112636-141592ba”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}